The phase III KEYNOTE-522 trial investigating Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as an adjuvant treatment after surgery met its dual primary endpoint of event-free survival for the treatment of patients with high-risk early-stage triple-negative breast cancer.
The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.
